Prenetics Global Ltd has announced a significant leadership change with the resignation of Chief Financial Officer (CFO) Stephen Hoi Chun Lo, effective December 30, 2026. This decision comes as Mr. Lo seeks new opportunities after eight years of service at the company. His departure is notable in the context of the pharmaceutical preparations sector, where stable leadership is essential for navigating market challenges.

In a filing with the U.S. Securities and Exchange Commission (SEC) on November 2, 2026, Prenetics expressed gratitude for Mr. Lo's contributions and confirmed that he will continue to support the company in an advisory capacity until his departure. The company will appoint Brian Rosin as the new principal financial and accounting officer, effective December 31, 2026, pending board approval.

Background

Prenetics Global Ltd, a company classified under the SIC code 2834 for Pharmaceutical Preparations, operates primarily in the life sciences sector. It is listed on the Nasdaq under the tickers PRE and PRENW. The company has been active in the market, as evidenced by its recent filings, including multiple 6-K forms and others related to financial disclosures.

What the Filing Says

The SEC filing details Mr. Lo's resignation and highlights the company's plans for succession. The document states, "On October 30, 2026, Stephen Hoi Chun Lo tendered his resignation as Chief Financial Officer... to pursue new opportunities." It also notes that Mr. Rosin currently serves as CFO of IM8 (US) LLC, Prenetics' main operating subsidiary.

Impact

This leadership transition may affect various stakeholders, including employees, investors, and partners within the pharmaceutical preparations industry. With Mr. Rosin stepping into the CFO role, his experience at IM8 (US) LLC may provide continuity and stability during this transition period.

What's Next

The filing does not specify what happens next beyond the planned transition of CFO responsibilities. The approval of Mr. Rosin's appointment by the board of directors will be a key step in ensuring a smooth leadership change.

For more details, the filing can be accessed through the SEC under accession number 0001628280-26-068674.